Vol 72, No 3 (2021)
Clinical vignette
Published online: 2021-03-22

open access

Page views 1029
Article views/downloads 447
Get Citation

Connect on Social Media

Connect on Social Media

Giant silent corticotrope pituitary adenoma in a patient with complicated clinical course

Ognian Kalev1, Marina Hodolic23, Berndt Tomancok4, Michael Sonnberger5, Markus Hutterer6, Daniela Ehrlich7, Robert Pichler8
Pubmed: 33749817
Endokrynol Pol 2021;72(3):282-283.

Abstract

Not required for Clinical Vignette.

Article available in PDF format

View PDF Download PDF file

References

  1. Dai C, Liu X, Ma W, et al. The Treatment of Refractory Pituitary Adenomas. Front Endocrinol (Lausanne). 2019; 10: 334.
  2. de Bruin C, Feelders RA, Lamberts SWJ, et al. Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome. Rev Endocr Metab Disord. 2009; 10(2): 91–102.
  3. de Herder WW, Reijs AEM, Feelders RA, et al. Diagnostic imaging of dopamine receptors in pituitary adenomas. Eur J Endocrinol. 2007; 156 Suppl 1: S53–S56.
  4. Liu H, Zakiniaeiz Y, Cosgrove KP, et al. Toward whole-brain dopamine movies: a critical review of PET imaging of dopamine transmission in the striatum and cortex. Brain Imaging Behav. 2019; 13(2): 314–322.
  5. de Bruin C, Pereira AM, Feelders RA, et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab. 2009; 94(4): 1118–1124.
  6. Gabalec F, Beranek M, Netuka D, et al. Dopamine 2 receptor expression in various pathological types of clinically non-functioning pituitary adenomas. Pituitary. 2012; 15(2): 222–226.